Roivant Sciences: Funding, Investors & Team (Sep 2026)
With the speedy delivery of cutting-edge treatments and technologies to patients, Roivant seeks to improve health. We accomplish this by establishing Vants, nimble, entrepreneurial biotech and healthcare technology businesses with a distinctive method for finding talent, coordinating incentives, and implementing technology. Many rare and fatal paediatric disorders, uterine fibroids, endometriosis, prostate cancer, Parkinson's disease, diabetes, and pulmonary arterial hypertension are among the ailments that are being treated by the medicines that are being developed by our family of firms. We concentrate on disease areas where company R&D spending is disproportionately little compared to societal medical demands. We also create technology-focused Vants aimed at enhancing the process of developing and marketing medications in addition to our biopharmaceutical companies.
Roivant Sciences has raised $400M across 2 funding rounds on record, the most recent an undisclosed round of $200M announced in Feb 2023.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Roivant Sciences Company Profile and Key Stats
Latest funding round on record: Feb 2023.
Roivant Sciences Funding Rounds
Roivant Sciences raised $200M in a Post-IPO Equity announced in Oct 2021.
1.3 years later, an undisclosed round of $200M was announced in Feb 2023.
Roivant Sciences Founders and Leadership Team
Contact details for the Roivant Sciences team: 1 of 2 have an email address on file.
Start 14-day free trial →Roivant Sciences Funding Compared to Other Biotechnology Startups
Roivant Sciences' latest round of $200M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Roivant Sciences in Biotechnology and New York
Companies Similar to Roivant Sciences
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Roivant Sciences Funding FAQs
What does Roivant Sciences do?
With the speedy delivery of cutting-edge treatments and technologies to patients, Roivant seeks to improve health. We accomplish this by establishing Vants, nimble, entrepreneurial biotech and healthcare technology businesses with a distinctive method for finding talent, coordinating incentives, and implementing technology. Many rare and fatal paediatric disorders, uterine fibroids, endometriosis, prostate cancer, Parkinson's disease, diabetes, and pulmonary arterial hypertension are among the ailments that are being treated by the medicines that are being developed by our family of firms. We concentrate on disease areas where company R&D spending is disproportionately little compared to societal medical demands. We also create technology-focused Vants aimed at enhancing the process of developing and marketing medications in addition to our biopharmaceutical companies.
How much funding has Roivant Sciences raised?
Roivant Sciences has raised $400M across 2 rounds on record. The most recent is an undisclosed round of $200M announced in Feb 2023.
When did Roivant Sciences last raise funding?
Roivant Sciences' most recent funding round on record is an undisclosed round of $200M, announced in Feb 2023.
Who founded Roivant Sciences?
FundedIQ lists Vivek Ramaswamy (Founder) at Roivant Sciences.
Who is the CEO of Roivant Sciences?
Regina Sav is listed as CEO at Roivant Sciences.
Where is Roivant Sciences headquartered?
Roivant Sciences is based in New York, United States.
How many employees does Roivant Sciences have?
Roivant Sciences is in the 501-1000 employee band.
How does Roivant Sciences' funding compare to other Biotechnology startups?
Roivant Sciences' latest round of $200M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Roivant Sciences Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Roivant Sciences is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.